GALMED PHARMACEUTICALS LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.395 USD | -1.00% |
|
-0.83% | -13.19% |
Presentation Operator MessageOperator (Operator)Good day, and welcome to Galmed Conference Cal...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Calendar
2025-05-06
- Q1 2025 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.399
USD
Average target price
1
USD
Spread / Average Target
+150.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.19% | 2.4M | |
| +8.67% | 114B | |
| +10.79% | 104B | |
| -12.83% | 22.41B | |
| -1.14% | 22.28B | |
| -5.24% | 19.07B | |
| -38.29% | 18B | |
| -5.03% | 17.89B | |
| +7.60% | 14.28B | |
| +35.72% | 12.55B |
- Stock Market
- Equities
- GLMD Stock
- News Galmed Pharmaceuticals Ltd.
- Transcript : Galmed Pharmaceuticals Ltd., Q3 2019 Earnings Call, Nov 06, 2019
